With this data, the first peptide antagonist, (D)PPA-1, was described in 2015, and designed using a mirror-image phage display method, binding to PD-L1 and blocking the PD-1/PD-L1 interaction and decreasing tumor growth in vivo [100]. Here, CD274 is linked to neoplasm.